Pre-Conference Workshop Day

Tuesday, September 3, 2024

9:30am | Workshop A

Exploring Cutting-Edge Novel Formats of Bispecific Antibodies for Next-Generation Therapeutic Applications

  • Arne Scheu CEO, Valink Therapeutics
  • Alex Martinko Director - Antibody Engineering & Design, Cartography Biosciences, Inc

Synopsis

  • Exploring the landscape of novel bispecific drugs including bispecific antibody-drug conjugates, CAR-T therapies and beyond
  • Leveraging advanced protein engineering techniques to design novel bispecific antibody constructs
  • Case studies highlighting successful applications of novel bispecific antibody formats across various disease indications
  • Optimizing novel antibody formats for enhanced target specificity, affinity, and stability
  • Addressing translational challenges and regulator considerations in advancing novel bispecific antibody formats into clinical trials
  • Exploring emerging trends and technological advancements shaping the future of bispecific antibody therapeutics
  • Gain insights into the design, development, and clinical translation of next-generation bispecific antibodies

9:30 | Workshop B

Maximizing Bispecific Antibody Efficacy in Solid Tumors & Overcoming the Tumor Microenvironment

  • Peng Wu Professor, The Scripps Research Institute

Synopsis

  • Leveraging innovative research to identify promising targets within the tumor microenvironment for bispecific antibody drugs
  • Optimizing bispecific antibody design and functionality for enhanced tumor penetration
  • Engineering strategies to enhance bispecific antibody penetration into the solid tumor microenvironment
  • Tailoring antibody formats and binding affinities for optimal target engagement and therapeutic effect
  • Evaluating preclinical models and predictive tools for assessing bispecific antibody penetration and activity in solid tumors
  • Addressing hurdles in translating preclinical bispecific success to clinical efficacy in solid tumor therapy
  • Discover innovative strategies to optimize antibody design, overcome translational challenges, and propel the field towards effective clinical solutions for combating solid tumor progression

12:30 | Lunch Break

1:30pm | Workshop C

Harnessing the Potential of Multispecific Drugs & Combinations for Enhanced Therapeutic Outcomes

  • Yue Liu Founder & Chief Executive Officer, Ab Therapeutics
  • Fernando Garces Chief Executive Officer, Biolyph LLC

Synopsis

  • Delving into the diverse landscape of multispecific drugs and their unique mechanisms of action
  • Optimizing multispecific drug design for areas of unmet need like solid tumors
  • Evaluating the clinical feasibility and therapeutic potential of novel combination approaches in diverse disease contexts
  • Addressing key translational hurdles in developing multispecific drug combinations for clinical use
  • Exploring emerging technology advancements driving the evolution of multispecific drugs and their use as combination therapies
  • Join this workshop to gain valuable insights into the landscape of multispecific drugs and combination approaches to unlock improved and synergistic therapeutic outcomes

1:30pm | Workshop D

Streamlining the Discovery of Next-Generation Bispecific Antibodies

Synopsis

  • Uncover the evolving landscape of bispecific antibody discovery platforms and cutting-edge technologies
  • Highlighting applications of novel discovery platforms in generating next-generation bispecific antibodies
  • Exploring advanced protein engineering techniques for the design and optimization of bispecific antibody scaffolds against novel targets
  • Enhancing the integration of high-throughput screening, structural biology, and functional assays
  • Overcoming challenges in scalability, manufacturability, and immunogenicity assessment during lead selection
  • Join this workshop to gain deeper insights into the latest advancements in bispecific antibody development platforms to accelerate and de-risk your own in-house bispecific discovery

4:30 pm End of Workshop Day